Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 October 2007, Vol. 110, No. 7, pp. 2242-2249.
Prepublished online as a Blood First Edition Paper on May 11, 2007; DOI 10.1182/blood-2007-03-066936.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-03-066936v1
110/7/2242    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Hare, T.
Right arrow Articles by Deininger, M. W. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Hare, T.
Right arrow Articles by Deininger, M. W. N.
Related Collections
Right arrow Oncogenes and Tumor Suppressors
Right arrow Perspectives
Right arrow Clinical Trials and Observations
Right arrow Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

PERSPECTIVE

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

Thomas O'Hare1,2, Christopher A. Eide2, and Michael W. N. Deininger2

1 Howard Hughes Medical Institute, Chevy Chase, MD; 2 Oregon Health & Science University Cancer Institute, Portland, OR

Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML). Here we examine predisposing factors underlying acquisition of KD mutations, evidence for acquisition of mutations before and during therapy, and whether the detection of a KD mutation universally implies resistance. We also provide a perspective on how the second-line Abl inhibitors dasatinib and nilotinib are faring in the treatment of imatinib-resistant CML, especially in relation to specific KD mutations. We discuss the growing importance of the multi-inhibitor–resistant 315T>I mutant and the therapeutic potential that a 315T>I inhibitor would have. Last, we assess the potential of Abl kinase inhibitor combinations to induce stable responses even in advanced CML and interpret the emerging data in the context of CML pathogenesis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
L. K. Kenealy, C. B. Christenson, and C. B. Williams
Current Therapies for Chronic Myeloid Leukemia
Journal of Pharmacy Practice, April 1, 2008; 21(2): 116 - 125.
[Abstract] [PDF]

Home page
 BloodHome page
J. S. Khorashad, D. Milojkovic, P. Mehta, M. Anand, S. Ghorashian, A. G. Reid, V. De Melo, A. Babb, H. de Lavallade, E. Olavarria, et al.
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
Blood, February 15, 2008; 111(4): 2378 - 2381.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. Baccarani, F. Pane, and G. Saglio
Monitoring treatment of chronic myeloid leukemia
Haematologica, February 1, 2008; 93(2): 161 - 169.
[Full Text] [PDF]

Home page
 haematolHome page
T. Ernst, P. Erben, M. C. Muller, P. Paschka, T. Schenk, J. Hoffmann, S. Kreil, P. La Rosee, R. Hehlmann, and A. Hochhaus
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
Haematologica, February 1, 2008; 93(2): 186 - 192.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
G. Saglio, F. Pane, and G. Martinelli
State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia
ASCO Educational Book, January 1, 2008; 2008(1): 313 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
M. W.N. Deininger
Imatinib Resistance and the Difficulty of Eradicating Leukemia Stem Cells
ASCO Educational Book, January 1, 2008; 2008(1): 318 - 323.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood, October 15, 2007; 110(8): 2828 - 2837.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
R. T. Williams, W. den Besten, and C. J. Sherr
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia
Genes & Dev., September 15, 2007; 21(18): 2283 - 2287.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020